Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Current Liabilities: 2016-2025

Historic Total Current Liabilities for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $104.3 million.

  • Rhythm Pharmaceuticals' Total Current Liabilities rose 6.83% to $104.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.3 million, marking a year-over-year increase of 6.83%. This contributed to the annual value of $115.5 million for FY2024, which is 109.26% up from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Total Current Liabilities stood at $104.3 million, which was down 19.46% from $129.5 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Total Current Liabilities registered a high of $129.5 million during Q2 2025, and its lowest value of $16.9 million during Q1 2021.
  • In the last 3 years, Rhythm Pharmaceuticals' Total Current Liabilities had a median value of $55.2 million in 2023 and averaged $78.6 million.
  • Within the past 5 years, the most significant YoY rise in Rhythm Pharmaceuticals' Total Current Liabilities was 180.56% (2022), while the steepest drop was 8.33% (2022).
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Total Current Liabilities stood at $43.4 million in 2021, then declined by 8.33% to $39.8 million in 2022, then spiked by 38.67% to $55.2 million in 2023, then soared by 109.26% to $115.5 million in 2024, then increased by 6.83% to $104.3 million in 2025.
  • Its Total Current Liabilities stands at $104.3 million for Q3 2025, versus $129.5 million for Q2 2025 and $111.8 million for Q1 2025.